author-photo

Lisa Rodriguez

Food and Drug Administration

3

Papers

121

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

2018 Oncologist
Show All
- Source
- Cite
- Save
Citations (8)
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

2018 Oncologist
Show All
- Source
- Cite
- Save
Citations (81)
FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

2017 Oncologist
Show All
- Source
- Cite
- Save
Citations (32)